|Bid||41.090 x 3200|
|Ask||41.100 x 1000|
|Day's Range||40.65 - 41.12|
|52 Week Range||32.32 - 41.64|
|PE Ratio (TTM)||10.98|
|Forward Dividend & Yield||1.36 (3.33%)|
|1y Target Est||N/A|
People who have a rare genetic mutation called essential fructosuria lack the primary enzyme needed to metabolize fructose, a natural sugar found in honey, fruits and vegetables. No ill consequences have been linked to the defect, save for an aversion to sweets, and it appears to have a significant benefit: Those who have it seem to be at little risk of obesity, type 2 diabetes or serious liver ailments. “When I started contacting people who were taking care of these patients, there was literally no one — I couldn’t find anyone — who was fat or had type 2 diabetes,” said Richard Johnson, a pioneering metabolic-disease scientist at the University of Denver.
Novo Nordisk’s (NVO) biopharmaceuticals segment generated revenues of 4.4 billion Danish kroner in the second quarter of 2018, a ~4% YoY (year-over-year) decline in local currencies.
In its Q2 2018 earnings conference call, Pfizer (PFE) updated its fiscal 2018 adjusted diluted earnings per share (or EPS) guidance from the previously projected range of $2.90–$3.00 to $2.95–$3.05. The midpoint of this updated EPS range implies a year-over-year (or YoY) rise of around 13%. While the company has completed share repurchases worth $6.1 billion to date in 2018, Pfizer has not factored in the impact of any additional share repurchases in its adjusted diluted EPS prediction for fiscal 2018. The company expects dilution due to share-based employee compensation to partly offset the impact of share repurchases in fiscal 2018.
IBM’s (IBM) Global Business Services unit, which represents ~21% of its total business, comprises its consulting, global business services, and application management offerings. In the last five quarters, the segment has grown 0.6% compounded annually, driven by improvement in its consulting business.
In its Q2 2018 earnings conference call, Pfizer (PFE) updated its fiscal 2018 revenue guidance from the previously projected range of $53.5 billion–$55.5 billion to $53.0 billion–$55.0 billion, mainly to account for the unfavorable foreign currency fluctuations from mid-April 2018 to mid-July 2018. Analysts have projected Pfizer’s fiscal 2018 revenues to come in around $54.2 billion, which would be a year-over-year (or YoY) rise of approximately 3.1%. Merck (MRK), Eli Lilly (LLY), and Novartis (NVS) are expected to report revenues close to $42.4 billion, $24.3 billion, and $52.4 billion, respectively, in fiscal 2018.
As discussed, GlaxoSmithKline’s three business segments—Pharmaceuticals, Vaccines, and Consumer Healthcare—all saw YoY (year-over-year) revenue growth in the second quarter, as shown in the graph below. Pharmaceuticals revenue fell 3% YoY to ~4.2 billion British pounds, as a result of 1% operating revenue growth and a 4% impact by foreign exchange. ...
Global pharmaceutical company GlaxoSmithKline (GSK) is aiming for sustainable growth by focusing on its business beyond pharmaceuticals. The company, which reports its financial results in British pounds, beat analysts’ EPS and revenue estimates of ~26.1 pence and 7.2 billion pounds in Q2 2018, reporting EPS of 28.1 pence and revenue of 7.3 billion pounds. The chart below shows GlaxoSmithKline’s revenue and EPS since the first quarter of 2017.
GlycoMimetics (NASDAQ:GLYC) issued a second quarter earnings report that investors will like. Its cash position was at high enough levels to cover future operational needs. GlycoMimetics ended the second quarter (Jun. 30, 2018) with $229.4 million in cash.
Healthcare has been a strong performer lately, and pharma stocks are garnering more interest from investors. Where we were: Worries about drug prices had been one knock against the pharma sector. Where we're headed: Investors are getting more interested in the stocks, on hopes that policy changes won't be a headwind.
Health care stocks including pharmaceutical giant Merck (NYSE:MRK) have gone on a nice run of late. Merk stock has gained over 20% just since early April, touching an all-time high this week. Q1 earnings that month seemed mixed, but the market reacted positively, and Merck raised guidance in the Q2 report late last month.
A deal with its roots in January's J.P. Morgan Healthcare Conference adds power to a small vaccine maker's quest to go after specialty vaccines amid a consolidating industry.
Sangamo Therapeutics reported second-quarter sales of $21.42 million, which just missed analysts’ estimate of $21.44 million in sales. This study evaluates SB-525 gene therapy for the treatment of hemophilia A. However, SGMO’s net loss declined on a sequential basis, and the company reported solid YoY (year-over-year) sales growth. Sangamo Therapeutics’ (SGMO) sales have risen ~160.0% on a YoY basis.
In the second quarter, Exelixis’s (EXEL) Cabometyx revenues grew ~74% YoY (year-over-year) to $141.1 million and ~9% sequentially. Cometriq generated revenues of $4.7 million, reflecting an ~11% sequential decline.
Analysts expect Pfizer’s (PFE) adjusted EPS to be $2.99 on revenue of $54.3 billion in 2018, a 3.4% rise compared to $52.5 billion in 2017. Analysts also expect a 10.9% rise in the company’s adjusted net income during 2018, mainly due to a fall in its selling, general, and administrative expenses as well as its lower research and development expenses as a percentage of its sales.
Aerie's (AERI) Q2 loss is wider than expected on account of higher expenses. Nevertheless, Rhopressa's sales beat estimates as demand picks up.
Pfizer (PFE) is focused on discovering, developing, and manufacturing healthcare products. Pfizer’s portfolio includes medicines, vaccines, and consumer healthcare products. Pfizer’s top line rose ~4% to $13.5 billion in the second quarter of 2018 compared to $12.9 billion in the second quarter of 2017.